PIPELINE
A regenerative ophthalmology pipeline.
One blood-derived regenerative science → a pipeline of assets. Dry eye is the lead; each new ocular-surface indication compounds platform value.
Discovery
Preclinical
Phase 1
Phase 2/3
Filing / Market
QASED — Autologous
Ocular surface comfort & health
On market
Current stage: Filing / Market
2015
R&D begins at Bascom Palmer
2023
Refined in clinical practice
2026
Pilot / proof of concept
Q4 2026
U.S. commercial launch
OB-1 — Allogeneic
Dry eye disease
Phase 2/3 (Regenerate 2)
Current stage: Phase 2/3
2025
R&D + pre-clinical safety studies
2026
Phase I clinical trial
2027–28
Phase II/III clinical trial
2029
FDA approval → U.S. launch
OB-2 — Allogeneic
Neurotrophic keratitis
Orphan · PreclinicalPreclinical
Current stage: Preclinical
OB-3 — Allogeneic
Pediatric ocular graft-versus-host disease
DiscoveryDiscovery
Current stage: Discovery